Vonvendi representative?

Who is the representative for Vonvendi?

Vonvendi is a recombinant von Willebrand factor (rVWF) for the treatment of von Willebrand disease (VWD) and acquired hemophilia A [1]. The treatment is marketed by CSL Behring, a subsidiary of the biopharmaceutical company CSL Limited.

CSL Behring: The Manufacturer of Vonvendi

CSL Behring, located in King of Prussia, Pennsylvania, is a global leader in the development, production, and marketing of plasma-derived therapies and recombinant products [2]. CSL Behring serves patients worldwide who suffer from rare and serious diseases.

According to its website, CSL Behring's portfolio includes products for the treatment of hemophilia, primary immune deficiencies, alpha-1 antitrypsin deficiency, and hereditary angioedema [3]. The company also has a comprehensive research and development program focused on innovative therapies and solutions for patients with rare and serious diseases.

Regulatory and Patent Information

Vonvendi was approved by the U.S. Food and Drug Administration (FDA) under the Orphan Drug Act on September 28, 2016 [4].

The product's manufacturing process is protected by the Orphan Drug Act and various patents. You can check the latest patents and regulatory status for Vonvendi through resources like DrugPatentWatch.com.

Clinical Data and Product Information

Vonvendi is recommended for the treatment of acute bleeding episodes in adult patients with von Willebrand disease (VWD) and acquired hemophilia A.

If you're looking for more information on CSL Behring's Vonvendi, including safety and efficacy data, dosage information, and product availability, you may find it on the company's website or FDA-approved product labeling.

References:
[1] CSL Behring. (2022). Vonvendi Summary of Product Characteristics. Retrieved from https://www.cslbehring.com/vonvendi-summary-of-product-characteristics/
[2] CSL Behring. (2022). About CSL Behring. Retrieved from https://www.cslbehring.com/about-csl-behring/
[3] CSL Behring. (2022). Product Portfolio. Retrieved from https://www.cslbehring.com/product-portfolio/
[4] U.S. Food and Drug Administration. (September 28, 2016). CSL Behring's vonvendi Approved for the Treatment of Adults with Acquired Hemophilia A and von Willebrand Disease. Retrieved from https://www.fda.gov/news-events/press-announcements/csl-behrings-vonvendi-approved-treatment-adults-acquired-hemophilia-a-and-von-willebrand-disease